CoChat
Sign Up
Cited by 156Neurotransmitter Receptor Influence on BehaviorTreatment of Major DepressionNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 58 of the 60 references it cites were found in a registry or an index.

Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats

Li, Simon Xi-Ming, Perry, Kenneth W, Wong, David T·2002·Neuropharmacology
DOI 10.1016/s0028-3908(01)00160-5
Open this paper in CoChat — free account

Abstract

The finding that serotonin (5-HT) can modulate dopamine (DA) and norepinephrine (NE) release in the brain has led us to hypothesize that fluoxetine, a selective 5-HT reuptake inhibitor, may influence the ability of bupropion, a preferential DA and NE dual reuptake inhibitor, to modulate extracellular DA and NE concentrations in some brain areas. The present study was designed to evaluate this hypothesis by assessing the effects of fluoxetine on bupropion-induced changes in extracellular monoamine concentrations by means of in vivo microdialysis. Three mesocorticolimbic areas including hypothalamus (Ht), prefrontal cortex (Pfc) and nucleus accumbens (Acb) were selected based on their relevance to depression and antidepressant actions. In the Ht of untreated rats, bupropion dose-dependently (s.c.) increased extracellular DA and NE concentrations either in single injection study or in sequential injection study. Thus, 10 mg/kg of bupropion had no effect on the DA and NE concentrations, while 30 mg/kg of bupropion induced transient but significant increases (about 240% of the baselines), and 100 mg/kg of bupropion induced marked and persistent increases (over 600% of the baselines) in the DA and NE concentrations. In the rats pre-treated with fluoxetine (10 mg/kg, s.c., 90 min interval), the threshold dose of bupropion (10 mg/kg) significantly increased the DA and NE concentrations to more than 350% of the baselines, and 30 mg/kg of bupropion markedly increased the DA and NE concentrations to more than 570% of the baselines in the Ht. The fluoxetine pre-treatment also potentiated the DA increases induced by 10 mg/kg of bupropion in the Pfc (260% for bupropion alone vs 357% for the combination) and in the Acb (224% vs 645%). The bupropion-induced NE increases were potentiated by fluoxetine mainly in the Ht. Bupropion did not significantly affect the extracellular 5-HT concentrations in all the 3 brain areas tested. In summary, the present study demonstrated that bupropion can increase extracellular DA and NE concentrations in several mesocorticolimbic areas, which may have an impact on bupropion's antidepressant actions. Furthermore, fluoxetine can potentiate the bupropion-induced DA and NE increases, which may produce more effective and rapid antidepressant actions.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0028-3908(01)00160-5

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 5

  1. Dubini, 1997, NE-selective versus 5-HT-selective antidepressant therapy: differential effects on social functioning, Journal of Psychopharmacology, 11, S17
  2. Ferris, 1993, Mechanism of antidepressant activity of bupropion, Journal of Clinical Psychiatry Monographs, 11, 2
  3. Fuller, 1992, Clinical applications of 5-HT uptake inhibitors, vol. 85, 255
  4. Gessa, 1994, Dopaminergic system in antidepressant action, Neuropsychopharmacology, 10, 47S
  5. Mayle, 1991, Elevation of catecholaminergic metabolite levels in the rat hypothalamus by an agonist of serotonin IC/2 receptors, MK212 (6-chloro-2(1-piperazinyl)pyrazine), Society for Neuroscience, 17, 407

Cited by

Sorted by citations

See all 156

Related

See all

Metadata

Authors
Li, S. X.-M., Perry, K. W., & Wong, D. T.
Affiliations
Eli Lilly (United States) (US)
Corresponding author
Perry, Kenneth W
ORCID
Wong, David T
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2002-02
Volume
42
Issue
2
Pages
181-190
ISSN
0028-3908 (ISSN-L)
DOI
10.1016/s0028-3908(01)00160-5
OpenAlex
W1971669832
Cited by
156
References
60
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2021: 2 · 2020: 5 · 2019: 3 · 2018: 3 · 2017: 5 · 2016: 4 · 2015: 4 · 2014: 4 · 2013: 14 · 2012: 11
FWCI
3.95
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Neuropharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
fluoxetine, bupropion, extracellular dopamine, serotonin, mesocorticolimbic system, hypothalamus, prefrontal cortex, nucleus accumbens, monoamine release, antidepressant mechanism, selective serotonin reuptake inhibitors, depression, drug interactions, microdialysis, rats
MeSH terms
Animals, Cerebral Cortex, Chromatography, High Pressure Liquid, Dopamine, Extracellular Space, Fluoxetine, Hematocrit, Limbic System, Male, Norepinephrine, Bupropion, Rats, Sprague-Dawley, Selective Serotonin Reuptake Inhibitors, Microdialysis, Dopamine Uptake Inhibitors, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review